Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting
about
The Mitogen-Activated Protein Kinase (MAPK) Pathway: Role in Immune Evasion by TrypanosomatidsDrugging the unfolded protein response in acute leukemiasPhosphoflow-Based Evaluation of Mek Inhibitors as Small-Molecule Therapeutics for B-Cell Precursor Acute Lymphoblastic LeukemiaGene network analysis shows immune-signaling and ERK1/2 as novel genetic markers for multiple addiction phenotypes: alcohol, smoking and opioid addiction.A novel somatic mutation in ACD induces telomere lengthening and apoptosis resistance in leukemia cellsMEK1 is required for the development of NRAS-driven leukemia.Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia.High hyperdiploid acute lymphoblastic leukemia (ALL)-A 25-year population-based survey of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group.Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma.Novel therapy for childhood acute lymphoblastic leukemia.Carboxyl terminus-truncated α1D-adrenoceptors inhibit the ERK pathway.Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes.Mutational analysis of the RAS/RAF/MEK/ERK signaling pathway in 260 Han Chinese patients with cervical carcinoma.w09, a novel autophagy enhancer, induces autophagy-dependent cell apoptosis via activation of the EGFR-mediated RAS-RAF1-MAP2K-MAPK1/3 pathway.Somatic MAP2K1 Mutations Are Associated with Extracranial Arteriovenous Malformation.Analysis of KRAS and NRAS Gene Mutations in Arab Asian Children With Acute Leukemia: High Frequency of RAS Mutations in Acute Lymphoblastic Leukemia.Perspectives of the Nrf-2 signaling pathway in cancer progression and therapy.B lymphoblastic leukemia/lymphoma: new insights into genetics, molecular aberrations, subclassification and targeted therapy.T-cell Acute Lymphoblastic Leukemia Cells Display Activation of Different Survival Pathways.Proteomic changes of CD4+/CD25+/forkhead box p3+ regulatory T cells in a 30-day rat model of sepsis survival.RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia.Inhibition of the NEDD8 conjugation pathway induces calcium-dependent compensatory activation of the pro-survival MEK/ERK pathway in acute lymphoblastic leukemia.Pathways of topological rank analysis (PoTRA): a novel method to detect pathways involved in hepatocellular carcinoma.New Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update.Importance of ERK1/2 in Regulation of Protein Translation during Oocyte Meiosis.Differential Co-expression and Regulatory Network Analysis Uncover the Relapse Factor and Mechanism of T Cell Acute Leukemia.DAXX promotes ovarian cancer ascites cell proliferation and migration by activating the ERK signaling pathway
P2860
Q26768552-E0743F5F-3EC5-4990-9E60-506108814516Q26801114-06A7A6AF-C1E3-4E2C-97C6-5199A710EFB0Q28547880-05162AE0-79E4-4199-948E-8333B825F5D9Q35686543-1D4F98FB-CDBD-4F0A-AAC9-9A4566659BAAQ35765789-6D88A449-295A-4907-B0B3-5FBAA6EE4A1AQ37696978-46FAB17D-9E32-492C-BEDC-26CD2EF95627Q38633437-18AE03DD-16BC-42AB-BD91-AD66C53B8A0EQ38800499-0B76B18C-16D6-471E-A8A6-ED0B345C15CEQ39270291-40156B5D-FBCC-4DD6-8565-ABC95F2F0C19Q39368957-A0E61D52-06D3-400F-8287-7F7593CD6BA7Q39794436-8BA8C07B-368D-467A-BB7C-F0AC01E6B2FDQ39992854-3882629D-AE5C-4EA8-B74E-7AF81F8056D7Q40092876-78B0A631-FA7E-46B1-8179-453DB18B9B02Q40209537-5393C164-C067-4B3D-BDDD-2D79CC8CF9D9Q40443186-CC40AD9C-140C-491B-8F0E-9F3DD89C775EQ41535044-C38696CA-67C4-4A38-9FB9-6D1732E70A7EQ41678966-276F1353-F2E3-4291-A73D-7E3A34429D38Q42371687-C14B0DE6-CC84-4022-939C-5D131EFB28AEQ47104126-EAC82DAB-486A-4D3D-AC09-756A6757C169Q47139508-B9AE380D-7472-4660-8A2D-5944AA02DA4AQ47875530-3CA76001-92F9-4783-8A0D-1C42051F12B1Q47884832-624C9B62-3D7C-4FC8-ACFA-2E1B90EB229DQ49787961-AA6A8736-0644-4D66-8C62-F09AF71395E3Q52318559-AEC8FF68-2B2D-4209-993C-2357BD7AD72FQ52593673-7728A423-9CF7-46F5-A08C-0029C5FA0BA6Q52729625-DBF132C6-3417-4FCD-B6E2-6E5FD14908BDQ55408034-FC0703DE-7431-4631-8CEB-E694B8EEDE62Q58598951-B033F013-B78D-473C-AEC3-EBE8F111E3A7
P2860
Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Ras/Raf/MEK/ERK Pathway Activa ...... and Its Therapeutic Targeting
@en
type
label
Ras/Raf/MEK/ERK Pathway Activa ...... and Its Therapeutic Targeting
@en
prefLabel
Ras/Raf/MEK/ERK Pathway Activa ...... and Its Therapeutic Targeting
@en
P2860
P356
P1476
Ras/Raf/MEK/ERK Pathway Activa ...... and Its Therapeutic Targeting
@en
P2093
Julie Anne Elizabeth Irving
Thomas Knight
P2860
P356
10.3389/FONC.2014.00160
P577
2014-06-24T00:00:00Z